{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:34:32Z","timestamp":1790890472055,"version":"4.1.0"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Oritavancin is a lipoglycopeptide antibiotic with in vitro bactericidal activity against gram-positive pathogens indicated for use in adults with acute bacterial skin and skin structure infections (ABSSSI). Its concentration-dependent activity and prolonged half-life provide a convenient single-dose alternative to multi-dose daily therapies for ABSSSI. This retrospective cohort study was conducted to quantify the clinical and economic advantages of using oritavancin compared to other antibiotic agents that have been historically effective for ABSSSI.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Seventy-nine patients received oritavancin who had failed previous outpatient antibiotic therapy (OPAT) for cellulitis or abscess and were subsequently readmitted to the hospital as an inpatient between 2016 and 2018. These patients were compared to a cohort of 28 patients receiving other antibiotics following OPAT failure and subsequent hospitalization for these two infection types. The primary clinical end point was average length of stay (aLOS) and secondary endpoints included readmission rates for the same indication at 30 and 90 days after discharge and the average hospital cost (aHC).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 107 patients were hospitalized for treatment of cellulitis or abscess. Demographic characteristics of both the oritavancin and comparator groups were similar except for the presence of diabetes. The primary clinical endpoint showed a non-significant decrease in aLOS between the oritavancin group versus comparator (2.12 days versus 2.59 days; p = 0.097). The secondary endpoints revealed lower readmission rates associated with oritavancin treatment at 30 and 90 days; the average hospital cost was 5.9% lower for patients that received oritavancin.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The results of this study demonstrate that oritavancin provides not only a single-dose alternative to multi-day therapies for skin and skin structure infections, but also a clinical and economic advantage compared to other antibiotic agents.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0248129","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T17:30:11Z","timestamp":1616088611000},"page":"e0248129","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Improved economic and clinical outcomes with oritavancin versus a comparator group for treatment of acute bacterial skin and skin structure infections in a community hospital"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9673-4241","authenticated-orcid":true,"given":"Kimberly","family":"Saddler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Sul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pruthvi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriams","family":"Castro-Lainez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1813-6403","authenticated-orcid":true,"given":"Mark L.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl","family":"Kosler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Lowery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Sierra-Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,3,18]]},"reference":[{"issue":"11","key":"pone.0248129.ref001","doi-asserted-by":"crossref","first-page":"e0143276","DOI":"10.1371\/journal.pone.0143276","article-title":"Rising United States hospital admissions for acute bacterial skin and skin structure infections: recent trends and economic impact","volume":"10","author":"KS Kaye","year":"2015","journal-title":"PLoS One"},{"issue":"S3","key":"pone.0248129.ref002","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1093\/cid\/ciz002","article-title":"Current epidemiology, etiology, and burden of acute skin infections in the United States","volume":"68","author":"KS Kaye","year":"2019","journal-title":"Clin Infect Dis"},{"key":"pone.0248129.ref003","unstructured":"The Patient Protection and Affordable Care Act (PPACA), Pub. L. No. 111\u2013148, 124 Stat. 119. 2010."},{"key":"pone.0248129.ref004","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s12879-015-1071-0","article-title":"Incidence of skin and soft tissue infections in ambulatory and inpatient settings, 2005\u20132010","volume":"15","author":"LG Miller","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"11","key":"pone.0248129.ref005","doi-asserted-by":"crossref","first-page":"e0206893","DOI":"10.1371\/journal.pone.0206893","article-title":"Age-based health and economic burden of skin and soft tissue infections in the United States, 2000 and 2012","volume":"13","author":"K Tun","year":"2018","journal-title":"PLoS One"},{"key":"pone.0248129.ref006","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/cid\/ciy509","article-title":"Decreasing incidence of skin and soft-tissue infections in 86 US emergency departments, 2009\u20132014","volume":"68","author":"E Morgan","year":"2019","journal-title":"Clin Infect Dis"},{"key":"pone.0248129.ref007","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1093\/cid\/ciz977","article-title":"National trends in incidence of purulent skin and soft tissue infections in patients presenting to ambulatory and emergency department settings, 2000\u20132015","volume":"70","author":"SA Fritz","journal-title":"Clin Infect Dis"},{"key":"pone.0248129.ref008","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1914433","article-title":"Multidrug-resistant bacterial infections in US hospitalized patients, 2012\u20132017","volume":"382","author":"JA Jernigan","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0248129.ref009","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","article-title":"SOLO I Investigators. Single-dose oritavancin in the treatment of acute bacterial skin infections","volume":"370","author":"GR Corey","year":"2014","journal-title":"N Engl J Med"},{"key":"pone.0248129.ref010","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciu778","article-title":"SOLO II Investigators. Single-dose oritavancin versus 7\u201310 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study","volume":"60","author":"GR Corey","year":"2015","journal-title":"Clin Infect Dis"},{"key":"pone.0248129.ref011","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ijantimicag.2016.07.019","article-title":"Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus","volume":"48","author":"GR Corey","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"pone.0248129.ref012","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw274","article-title":"Efficacy and safety of oritavancin relative to vancomycin for patients with acute bacterial skin and skin structure infections (ABSSSI) in the outpatient setting: results from the SOLO clinical trials","volume":"4","author":"TP Lodise","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"pone.0248129.ref013","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5811\/westjem.2014.11.24133","article-title":"Factors associated with decision to hospitalize emergency department patients with skin and soft tissue infection","volume":"16","author":"DA Talan","year":"2015","journal-title":"West J Emerg Med"},{"key":"pone.0248129.ref014","unstructured":"US Food and Drug Administration. Guidance for Industry. Acute bacterial skin and skin structure Infections: developing drugs for treatment. Silver Spring, MD: FDA; October 2013."},{"issue":"3","key":"pone.0248129.ref015","doi-asserted-by":"crossref","first-page":"A282","DOI":"10.1016\/j.jval.2014.03.1642","article-title":"Severity and costs of acute bacterial skin and skin structure infections by treatment setting: an application of the Eron Classification to a real-world database","volume":"17","author":"K Sulham","year":"2014","journal-title":"Value in Health"},{"issue":"3","key":"pone.0248129.ref016","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/21548331.2015.1076325","article-title":"Hospital admission patterns in adult patients with skin and soft tissue infections: Identification of potentially avoidable hospital admissions through a retrospective database analysis","volume":"43","author":"TP Lodise","year":"2015","journal-title":"Hosp Pract"},{"issue":"Suppl 1","key":"pone.0248129.ref017","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/jac\/dkg466","article-title":"Managing skin and soft tissue infections: expert panel recommendations on key decision points","volume":"52","author":"LJ Eron","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"pone.0248129.ref018","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40121-016-0119-9","article-title":"Single-dose oritavancin treatment of acute bacterial skin and skin structure infections: SOLO trial efficacy by Eron severity and management setting","volume":"5","author":"DH Deck","year":"2016","journal-title":"Infect Dis Ther"},{"key":"pone.0248129.ref019","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.clinthera.2015.11.014","article-title":"Economic impact of oritavancin for the treatment of acute bacterial skin and skin structure infections in the emergency department or observation setting: cost savings associated with avoidable hospitalizations","volume":"38","author":"TP Lodise","year":"2016","journal-title":"Clin Ther"},{"key":"pone.0248129.ref020","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12941-016-0175-8","article-title":"A prospective observational cohort study in primary care practices to identify factors associated with treatment failure in Staphylococcus aureus skin and soft tissue infections","volume":"15","author":"GC Lee","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"5","key":"pone.0248129.ref021","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1128\/AAC.02626-15","article-title":"Relationship between adherence to oral antibiotics and postdischarge clinical outcomes among patients hospitalized with Staphylococcus aureus skin infections","volume":"60","author":"SJ Eells","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0248129.ref022","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jgar.2020.08.022","article-title":"Italian young doctors\u2019 knowledge, attitudes and practices on antibiotic use and resistance: A national cross-sectional survey","volume":"23","author":"F Di Gennaro","journal-title":"Journal of Global Antimicrobial Resistance"},{"key":"pone.0248129.ref023","first-page":"1","article-title":"Assessing the economic value of avoiding hospital admissions by shifting the management of gram\u00fe acute bacterial skin and skin-structure infections to an outpatient care setting","author":"V Ektare","year":"2015","journal-title":"Journal of Medical Economics"},{"key":"pone.0248129.ref024","unstructured":"Armstrong S, Liao N, Fan W, Sulham K. Admission rate and length of stay for skin infection patients in US hospitals: use of oritavancin is associated with lower rates of hospital admission and shorter length of stay. Poster 688. ASM Microbe 2018. June 7\u201311, 2018; Atlanta, GA."},{"key":"pone.0248129.ref025","unstructured":"Fast Facts on U.S. Hospitals, 2019. American Hospital Association. https:\/\/www.aha.org\/statistics\/fast-facts-us-hospitals. Accessed June 26, 2019."},{"key":"pone.0248129.ref026","unstructured":"FDA. Framework for FDA\u2019s real-world evidence program. December 2018. https:\/\/www.fda.gov\/media\/120060\/download. Accessed 31 July 2019."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0248129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T17:30:41Z","timestamp":1616088641000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0248129"}},"subtitle":[],"editor":[{"given":"Francesco","family":"Di Gennaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,18]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0248129","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,18]]}}}